CryoLife, Inc. (CRY) Rating Reiterated by Northland Securities

CryoLife, Inc. (NYSE:CRY)‘s stock had its “buy” rating reiterated by equities research analysts at Northland Securities in a report issued on Monday. They currently have a $23.50 target price on the medical equipment provider’s stock. Northland Securities’ price objective would suggest a potential upside of 21.45% from the company’s previous close.

CRY has been the subject of several other reports. BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. TheStreet lowered CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research lowered CryoLife from a “buy” rating to a “sell” rating in a research report on Wednesday, August 2nd. Lake Street Capital upped their price target on CryoLife to $26.00 and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Canaccord Genuity restated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $23.63.

Shares of CryoLife (NYSE CRY) opened at $19.35 on Monday. CryoLife has a 52 week low of $14.02 and a 52 week high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $637.37, a P/E ratio of 46.46 and a beta of 0.82.

CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. During the same period in the previous year, the business earned $0.13 EPS. CryoLife’s quarterly revenue was down 2.9% on a year-over-year basis. equities analysts anticipate that CryoLife will post 0.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/11/15/cryolife-inc-cry-rating-reiterated-by-northland-securities.html.

In related news, CEO James P. Mackin sold 43,050 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares in the company, valued at $8,800,633.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James P. Mackin sold 125,000 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the transaction, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Insiders sold 209,240 shares of company stock valued at $4,495,465 over the last 90 days. Company insiders own 6.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its position in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock worth $221,000 after acquiring an additional 100 shares during the period. Municipal Employees Retirement System of Michigan grew its position in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 190 shares during the period. Creative Planning grew its position in CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after acquiring an additional 200 shares during the period. Arizona State Retirement System grew its position in CryoLife by 1.4% in the second quarter. Arizona State Retirement System now owns 14,254 shares of the medical equipment provider’s stock worth $284,000 after acquiring an additional 200 shares during the period. Finally, Wells Fargo & Company MN grew its position in CryoLife by 0.9% in the second quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock worth $624,000 after acquiring an additional 271 shares during the period. Institutional investors own 70.34% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply